Categories: Market Research

Global Enzyme Replacement Therapy Market Size and Forecast 2024-2033| BioMarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc

Alpha-galactosidase (3d structure), administered as enzyme replacement therapy, a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins.

The Enzyme Replacement Therapy Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Enzyme Replacement Therapy Market:

https://www.thebusinessresearchcompany.com/report/enzyme-replacement-therapy-global-market-report

According to The Business Research Company’s Enzyme Replacement Therapy Global Market Report 2024, The enzyme replacement therapy market size has grown strongly in recent years. It will grow from $10.85 billion in 2023 to $11.72 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to growing early therapeutic discoveries, pioneering treatment approvals, expanded disease understanding, clinical success stories, regulatory support and incentives.

The enzyme replacement therapy market size is expected to see strong growth in the next few years. It will grow to $16.21 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing patient access to healthcare, tailored therapies and personalized medicine, regulatory landscape changes, growing patient population awareness. Major trends in the forecast period include digital health integration, focus on patient-centric solutions, emerging biomarker research, precision medicine approach.

The rising prevalence of rare, chronic, and inherited disorders is expected to propel the growth of the enzyme replacement therapy market going forward. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Chronic diseases are more common in elderly people and typically can be controlled but not eradicated. For instance, in January 2023, according to a report issued by the US-based National Library of Medicine, which is operated by the federal government, the number of people in the USA aged 50 and older who have at least one chronic condition will increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the rising prevalence of rare, chronic, and inherited disorders will drive the growth of the enzyme replacement therapy market going forward.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10512&type=smp

The enzyme replacement therapy market covered in this report is segmented –

1) By Enzyme Type: Agalsidase Alfa, Agalsidase Beta, Galsulfase, Other Enzyme Types

2) By Route Of Administration: Oral, Parenteral

3) By Application: Gaucher Disease, Pompe Disease, Fabry Disease, Other Applications

4) By End-Users: Hospitals, Infusion Centers, Other End-Users

Product approvals have emerged as the key trend gaining popularity in the enzyme replacement therapy market. Several enzyme replacement therapy medications introduced by large players are getting approvals in the market. For instance, in February 2023, the Food and Drug Administration, a US-based federal agency of the Department of Health, approved Lamzede (velmanase alfa), the first enzyme replacement therapy approved in the United States for the treatment of non-central neurological indications of alpha-mannosidosis, a rare genetic disorder characterized by an absence of the alpha-mannosidase enzyme in the body. Lamzede helps patients regain normal cellular function by acting similarly to the alpha-mannosidase enzyme in their bodies, restoring healthy cellular functioning in patients. Lamzede is administered to patients once a week as a 10mg injection.

The enzyme replacement therapy market report table of contents includes:

1. Executive Summary

2. Enzyme Replacement Therapy Market Characteristics

3. Enzyme Replacement Therapy Market Trends And Strategies

4. Enzyme Replacement Therapy Market – Macro Economic Scenario

5. Global Enzyme Replacement Therapy Market Size and Growt

26. South America Enzyme Replacement Therapy Market

27. Brazil Enzyme Replacement Therapy Market

28. Middle East Enzyme Replacement Therapy Market

29. Africa Enzyme Replacement Therapy Market

30. Enzyme Replacement Therapy Market Competitive Landscape And Company Profiles

Top Major Players: